Pacira Biosciences, Inc. (PCRX)
23.42
+0.21
(+0.90%)
USD |
NASDAQ |
Jun 10, 16:00
23.43
+0.01
(+0.04%)
After-Hours: 20:00
Pacira Biosciences Gross Profit Margin (Quarterly) : 71.40% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 71.40% |
| December 31, 2025 | 72.26% |
| September 30, 2025 | 72.93% |
| June 30, 2025 | 69.53% |
| March 31, 2025 | 71.21% |
| December 31, 2024 | 71.05% |
| September 30, 2024 | 68.45% |
| June 30, 2024 | 67.09% |
| March 31, 2024 | 63.06% |
| December 31, 2023 | 65.78% |
| September 30, 2023 | 67.01% |
| June 30, 2023 | 63.10% |
| March 31, 2023 | 60.50% |
| December 31, 2022 | 55.66% |
| September 30, 2022 | 61.19% |
| June 30, 2022 | 61.66% |
| March 31, 2022 | 68.10% |
| December 31, 2021 | 70.69% |
| September 30, 2021 | 71.33% |
| June 30, 2021 | 72.55% |
| March 31, 2021 | 72.01% |
| December 31, 2020 | 71.55% |
| September 30, 2020 | 72.80% |
| June 30, 2020 | 67.85% |
| March 31, 2020 | 70.01% |
| Date | Value |
|---|---|
| December 31, 2019 | 72.33% |
| September 30, 2019 | 76.82% |
| June 30, 2019 | 73.71% |
| March 31, 2019 | 70.10% |
| December 31, 2018 | 74.79% |
| September 30, 2018 | 77.15% |
| June 30, 2018 | 75.13% |
| March 31, 2018 | 69.33% |
| December 31, 2017 | 73.07% |
| September 30, 2017 | 72.93% |
| June 30, 2017 | 66.43% |
| March 31, 2017 | 64.52% |
| December 31, 2016 | 67.60% |
| September 30, 2016 | 36.87% |
| June 30, 2016 | 66.90% |
| March 31, 2016 | 69.03% |
| December 31, 2015 | 71.97% |
| September 30, 2015 | 74.44% |
| June 30, 2015 | 68.00% |
| March 31, 2015 | 69.85% |
| December 31, 2014 | 69.30% |
| September 30, 2014 | 60.82% |
| June 30, 2014 | 57.69% |
| March 31, 2014 | 50.56% |
| December 31, 2013 | 45.25% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 98.25% |
| Bristol Myers Squibb Co. | 66.29% |
| ANI Pharmaceuticals, Inc. | 51.78% |
| Assertio Holdings, Inc. | 13.91% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 0.71% |
| Return on Assets | 0.37% |
| Return on Invested Capital | 0.42% |
| Profit Margin (Quarterly) | 1.64% |
| Operating Margin (Quarterly) | -0.32% |
| Return on Net Operating Assets | 0.59% |